This exclusive report dives deep into the global Cancer Registry Software Market, providing a thorough analysis. It looks at AI-powered auto-abstraction, the requirements for EHR interoperability and offers insights from various regions. Key components include competitive benchmarking, market dynamics and assessments of cutting-edge cloud-native solutions and population health-integrated lifecycles. The global Cancer Registry Software Market size was valued at US$ 85.44 Million in 2025 and is poised to grow from US$ 98.23 Million in 2026 to 265.77 Million by 2033, growing at a CAGR of 12.50% in the forecast period (2026-2033). The analysis encompasses market segmentation by software type, deployment model, and geographic region, with particular emphasis on the transformative role of artificial intelligence in automating case abstraction and enhancing data quality assurance across oncology networks globally.
Market Size (2026)
$85.44M
Projected (2033)
$265.77M
CAGR
12.50%
Published
May 2026
Select User License
Selected
PDF Report
USD 4,900
USD 3,200
The Cancer Registry Software Market is valued at $85.44M and is projected to grow at a CAGR of 12.50% during 2026 - 2033. North America holds the largest regional share, while Asia-Pacific (12.5%–14.8% CAGR) is the fastest-growing market.
Study Period
2020 - 2033
Market Size (2026)
$85.44M
CAGR (2026 - 2033)
12.50%
Largest Market
North America
Fastest Growing
Asia-Pacific (12.5%–14.8% CAGR)
Market Concentration
Medium
*Disclaimer: Major Players sorted in no particular order
Source: Claritas Intelligence — Primary & Secondary Research, 2026. All market size figures in USD unless otherwise stated.
Global Cancer Registry Software market valued at $85.44M in 2026, projected to reach $265.77M by 2033 at 12.50% CAGR
Key growth driver: Growing need for cancer data management among hospitals, research institutions and public health organizations (High, +3.5% CAGR impact)
North America holds the largest market share, while Asia-Pacific (12.5%–14.8% CAGR) is the fastest-growing region
AI Impact: The Cancer Registry Software Market is being changed by Artificial Intelligence in a way. Artificial Intelligence is taking the way of doing things, which was manual coding and turning it into something new with Artificial Intelligence.
9 leading companies profiled including Ordinate Corporation, Volpara Health Limited, Health Catalyst and 6 more
The Cancer Registry Software Market is being changed by Artificial Intelligence in a way. Artificial Intelligence is taking the way of doing things, which was manual coding and turning it into something new with Artificial Intelligence. This is making a difference because it is making Automated Auto-Abstraction and Multimodal Analytics better. Now the industry does not have to spend much time on paperwork because Autonomous Data Calibration is doing the work. These systems use Artificial Intelligence and special computer programs to look at doctor's notes and lab reports in time.
They can even figure out what codes to use, like the ICD-O codes, all on their own. By the year 2026 Artificial Intelligence will be able to help make sure the data is correct before it is sent in. This means that Artificial Intelligence will be able to find mistakes or missing information like tumor markers before it is too late. This is a deal because it will help get rid of the old problem of having too much work to do and not enough time to do it. Artificial Intelligence is also helping with research. Keeping things safe.
Artificial Intelligence is like a security guard for the cancer research field. It helps keep peoples information safe by looking for risks and flagging them. In the year 2026 Artificial Intelligence will be able to look at sets of data to find out if there are any problems. It can even find out if someone's private information might be at risk of being seen by someone who should not see it. The Cancer Registry Software Market is also using Artificial Intelligence to get an understanding of cancer.
Artificial Intelligence is helping to match up data from cancer registries with information from trials and studies on how well drugs work. This is helping to make the Cancer Registry Software Market a key part of making public health better. It is doing this by using computer programs to predict what might happen to people with cancer and by looking at how different groups of people are affected by cancer. The Cancer Registry Software Market is becoming a part of making healthcare more efficient and effective thanks, to Artificial Intelligence.
The cancer registry software market has evolved from being just a specialized administrative tool to becoming a vital clinical asset in the global oncology landscape. Today, this field is characterized by the essential integration of automated case abstraction and natural language processing (NLP), enabling the swift processing of unstructured data from pathology reports and electronic health records. This shift is largely driven by the industry-wide push for real-world evidence (RWE), as healthcare providers and pharmaceutical researchers depend on these platforms to monitor long-term patient outcomes, treatment effectiveness, and survivorship across various populations.
A key trend is the rise of interoperable, cloud-native systems that promote smooth data sharing between regional registries and national surveillance programs, all while upholding strict global privacy standards. Companies are focusing on AI-powered quality assurance tools to ease the workload on the limited number of certified tumor registrars, ensuring the accuracy of data for complex genomic and multi-modal treatment tracking. The market is also seeing a strategic enhancement in population health management, with software now providing predictive modeling to pinpoint high-risk disparities.
This professionalized setting reflects a market that has matured due to rigorous regulatory reporting requirements and a commitment to precision oncology, positioning cancer registry software as a crucial, data-rich foundation for evidence-based cancer control and clinical research.
| Year | Market Size (USD Billion) | Period |
|---|---|---|
| 2026 | $85.44B | Forecast |
| 2027 | $100.48B | Forecast |
| 2028 | $118.16B | Forecast |
| 2029 | $138.96B | Forecast |
| 2030 | $163.41B | Forecast |
| 2031 | $192.17B | Forecast |
| 2032 | $226.00B | Forecast |
| 2033 | $265.77B | Forecast |
Source: Claritas Intelligence — Primary & Secondary Research, 2026. All market size figures in USD unless otherwise stated.
Base Year: 2025Hospitals, research institutions and public health organizations use cancer registry software to collect organize and analyse information. This helps them to make decisions about patient care track cancer trends and see how well treatments are working.
These systems use Artificial Intelligence and special computer programs to look at doctor's notes and lab reports in time. They can even figure out what codes to use, like the ICD-O codes, all on their own.
A key trend is the rise of interoperable, cloud-native systems that promote smooth data sharing between regional registries and national surveillance programs, all while upholding strict global privacy standards.
This shift is largely driven by the industry-wide push for real-world evidence (RWE), as healthcare providers and pharmaceutical researchers depend on these platforms to monitor long-term patient outcomes, treatment effectiveness, and survivorship across various populations.
One of the challenges is getting all the data from different sources to match up and make sense. Doctors and hospitals get information from lots of places like patient records, labs and imaging systems. This can make it hard to keep all the data accurate and complete.
Sometimes the way people code and report data can be different and this can cause problems.
Despite the growth rates Europe faces challenges related to data privacy rules. This has led to the creation of registry modules that protect privacy.
There are some opportunities for cancer registry software. More and more people are using cancer registry data to do research plan care and understand healthcare trends. If cancer registry software can work well with healthcare systems it will be easier for people to get the data they need. This can help clinicians. Policymakers understand cancer trends and make good decisions about patient care. Cancer registry software can help people get the information they need in time and make good decisions about cancer care. Cancer registry software is really important, for cancer care. Can help people get better.
Expanding AI-driven predictive modeling capabilities enables population health organizations to identify high-risk disparities and stratify patient cohorts for targeted interventions. The growing pharmaceutical industry demand for real-world evidence linkage between cancer registries and clinical trial databases creates substantial revenue opportunities for vendors offering integrated data-sharing platforms.
| Region | Market Share | Growth Rate |
|---|---|---|
| North America | 26.2% | 6.37%–10.1%% CAGR |
| Europe | 20.2% | 10.5%–11.0%% CAGR |
| Asia Pacific | 16.8% | 11.74%–14.0%% CAGRFastest |
| Latin America | 18.4% | 10.6%–13.0%% CAGR |
| Middle East & Africa | 18.4% | 10.6%–13.0%% CAGR |
Source: Claritas Intelligence — Primary & Secondary Research, 2026.
Ordinate Corporation Volpara Health Limited Health Catalyst Elekta Oracle ONCO, Inc. IBM MCKESSON CORPORATION Conduent, Inc. The competitive landscape comprises established healthcare IT vendors and specialized oncology informatics companies. Volpara Health Limited recently launched Volpara Quiver software for MQSA compliance management at the Society for Breast Imaging symposium in April 2024. Health Catalyst announced UnityPoint Health's migration to its Health Catalyst Ignite Data and Analytics platform in November 2025, demonstrating continued market consolidation around modern data architecture solutions. These players compete on AI automation capabilities, EHR integration depth, cloud scalability, and regulatory compliance features.
MONTREAL, April 11, 2024 Volpara Health Technologies Ltd. (ASX: VHT), a global leader in software for the early detection and prevention of cancer, today debuted a new central, digital destination to manage mammography systems, staff credentials and professional development in support of compliance with the Food & Drug Administration's Mammography Quality Standards Act (MQSA). Volpara Quiver software is featured at the Society for Breast Imaging's (SBI) annual symposium alongside the company's suite of solutions for assessing breast density, mammography quality and evaluating cancer risk.
SALT LAKE CITY, Utah Nov. 10, 2025 Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that UnityPoint Health, an integrated non-profit health system that provides care throughout Iowa, western Illinois and southern Wisconsin in not-for-profit hospitals, clinics, and home health settings, is set to migrate from Health Catalyst's legacy data platform to its modern data platform, Health Catalyst Ignite Data and Analytics.
The cancer registry software market was valued at USD 85.44 million in 2025 and is projected to reach USD 265.77 million by 2033. This represents a compound annual growth rate (CAGR) of 12.5% over the forecast period, reflecting strong demand for integrated oncology data management solutions globally. See our market size analysis →
The market is expanding at a CAGR of 12.5% from 2026 to 2033. Key growth drivers include the adoption of automated case abstraction technology, natural language processing (NLP) integration for pathology report analysis, and healthcare systems' increasing focus on real-world evidence (RWE) to support clinical decision-making. See our growth forecast → See our key growth drivers →
Automated case abstraction and NLP-enabled data processing represent the fastest-growing segments within the cancer registry software market. These technologies enable rapid extraction of unstructured data from electronic health records and pathology reports, improving operational efficiency and clinical insights for oncology centers. See our segment analysis →
North America holds the largest market share due to advanced healthcare infrastructure, high EHR adoption, and regulatory mandates for cancer data reporting. However, Asia-Pacific is the fastest-growing region with a CAGR of 12.5%–14.8%, driven by expanding oncology centers and digital health investments across China, India, and Southeast Asia. See our growth forecast → See our geography analysis →
Leading vendors include Ordinate Corporation, Volpara Health Limited, Health Catalyst, Elekta, and Oracle. These companies provide comprehensive cancer registry platforms with integrated NLP, automated abstraction, and real-world evidence analytics capabilities to support oncology practices and healthcare systems.
Primary drivers include the industry-wide adoption of AI-powered natural language processing for automated case abstraction from unstructured clinical data, and healthcare systems' increasing demand for real-world evidence (RWE) to improve oncology outcomes. Regulatory requirements and value-based care models also accelerate market expansion globally.
Key challenges include data interoperability issues across fragmented EHR systems, high implementation costs for small healthcare facilities, and concerns about data privacy and compliance with HIPAA and international regulations. Additionally, the shortage of skilled professionals to manage complex registry systems limits adoption in emerging markets. See our market challenges → See our emerging opportunities →
Major opportunities include the integration of advanced AI and machine learning for predictive oncology analytics, expansion into emerging markets with growing cancer prevalence, and development of cloud-based solutions for cost-effective remote access. Partnerships with health IT vendors and pharma companies for clinical trial support also present significant growth avenues. See our emerging opportunities →
How this analysis was conducted
Primary Research
Secondary Research
Access detailed analysis, data tables, and strategic recommendations.